Drugs / CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC
CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04571632 | Sep 2020 → Dec 2023 | non-small cell lung carcinoma | University Hospital Brussels | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC | “CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be administered by intratumoral injection in the lesions that were injected by avelumab en ipilimumab on day 1 (approximately 24...” NCT04571632 ↗ |
| Modality | Cell therapy | “autologous, non-substantially manipulated CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be intratumorally administered.” NCT04571632 ↗ |
| Route | Other | “CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be administered by intratumoral injection” NCT04571632 ↗ |